Does Long-Term ICS Use Increase Fracture Risk in COPD Patients?

By February 05, 2018

Long-term ICS exposure at high doses was associated with a modest but significant increase in the risk of hip or upper extremity fractures.

New LABA, LAMA Use May Increase Cardiovascular Disease Risk in COPD

January 04, 2018

New use of long-acting 2-agonists, antimuscarinic antagonists tied to higher CVD risk in first 30 days

First Nebulized LAMA Approved for COPD

By December 06, 2017

Adults treated with Lonhala Magnair showed statistically significant and clinically important changes from baseline in trough forced expiratory volume in 1 second (FEV1) at Week 12 vs placebo.

COPD Exacerbation Risk Reduced With LAMA Plus LABA

October 04, 2017

Also might result in greater improvement in FEV1 than LABA plus corticosteroids

Single Inhaler Triple Therapy Approved for COPD

By September 18, 2017

Trelegy Ellipta combines fluticasone furoate, an inhaled corticosteroid with umeclidinium, an anticholinergic and vilanterol, a long-acting β2-adrenergic agonist (LABA).

Symbicort Gains Expanded COPD Indication

By September 14, 2017

The studies examined the efficacy of Symbicort pressurized metered dose inhaler (pMDI) 160/4.5mcg vs. formoterol 4.5mcg in reducing COPD exacerbations in adults with moderate to severe COPD.

Statin Use May Reduce Mortality Risk in COPD

September 08, 2017

Statin exposure associated with lower all-cause, pulmonary mortality

Tiotropium Evaluated in Mild to Moderate COPD

September 07, 2017

Daily inhaled dose tied to improvements in FEV1 compared to placebo

Healthy Diet May Lower COPD Risk

February 24, 2017

In current smokers, each extra daily serving tied to an 8 percent lower risk

Efficacy of COPD Combo Therapies Compared

By February 23, 2017

Clinical guidelines currently recommend LABA/LAMA therapy as an alternative to LABA/ICS but evidence on the comparative effectiveness of these combination therapies for COPD is limited.